Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension

Life Sciences

Volumn 74, Issue 10, 2004, Pages 1211-1224

  Simko, Fedor ^a   Matuskova, Jana ^a   Luptak, Ivan ^a   Krajcirovicova, Kristina ^a   Kucharska, Jarmila ^a   Gvozdjakova, Anna ^a   Babal, Pavel ^a   Pechanova, Olga ^b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Aorta remodeling; Fibrosis; L NAME; Left ventricular hypertrophy; Nitric oxide; NO deficient hypertension; Simvastatin

Indexed keywords

DNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; SIMVASTATIN; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BRAIN; CONTROLLED STUDY; DNA CONTENT; DNA DETERMINATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HYPERTENSION; KIDNEY; MALE; NONHUMAN; PROPHYLAXIS; RAT;

ANIMALIA;

EID: 0346880050     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.07.032     Document Type: Article

References (46)

1. Babal P., Pechanova O., Bernatova I., Stvrtina S. Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histology and Histopathology. 12:1997;623-629.
2. Bernatova I., Pechanova O., Pelouch V., Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. Journal of Molecular and Cellular Cardiology. 32:2000;177-185.
3. Bernatova I., Pechanova O., Simko F. Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiological Research. 45:1996;311-316.
4. Bernatova I., Pechanova O., Simko F. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Experimental Physiology. 84:1999;1095-1105.
5. Bliznakov E.G. Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Bayol case - a modern Pandora's box. Biomedicine and Pharmacotherapy. 56:2002;56-59.
6. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proceedings of the National Academy of Sciences of the United States of America. 87:1990;682-685.
7. Brown L., Fenning A., Shek A., Burstow D. Reversal of cardiovascular remodeling with candesartan. Journal of the Renin, Angiotensin and Aldosterone System. 2(suppl 1):2001;S141-S147.
8. Dechend R., Fiebler A., Lindschau C., Bischoff H., Muller D., Park J.K., Dietz R., Haller H., Luft F.C. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. American Journal of Hypertension. 14(6Pt2):2001;55S-61S.
9. Dechend R., Fiebeler A., Park J.K., Muller D.N., Theuer J., Mervaala E., Bieringer M., Gulba D., Dietz R., Luft F.C., Haller R.H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation. 104:2001;576-581.
10. Forte P., Copland M., Smith L.M., Milne E., Sutherland J., Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet. 349:1997;837-842.
11. Gerova M., Masanova C., Pavlasek J. Inhibition of NO synthase activity in the posterior hypothalamus increases blood pressure in rat. Physiological Research. 44:1995;131-134.
12. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
13. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 105:2002;868-873.
14. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanches-Pascuala R., Hernandez G., Diaz C., Lamas C. Effects of the 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation. 101:1998;2711-2719.
15. Holecyova A., Torok J., Bernatova I., Pechanova O. Restriction of nitric oxide rather than elevated blood pressure is responsible for alterations of vascular responses in nitric oxide deficient hypertension. Physiological Research. 45:1996;317-321.
16. K-Laflamme A., Foucart S., Moreau P., Lambert C., Cardinal R., De Champlain J. Sympathetic functions in NG-nitro-L-arginine-methylester-induced hypertension: modulation by the renin-angiotensin system. Journal of Hypertension. 16:1998;63-76.
17. Kucharska J., Gvozdjakova A., Mizera S., Braunova Z., Schreinerova Z., Schramekova E., Pechan I., Fabian J. Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study. Physiolocial Research. 47:1998;399-404.
18. Kucharska J., Braunova Z., Ulicna O., Zlatos L., Gvozdjakova A. Deficit of coenzyme Q in heart and liver mitochondria of rats with streptozotocin- induced diabetes. Physiological Research. 49:2000;411-418.
19. Lang J.K., Gohil K., Packer L. Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Analytical Biochemistry. 157:1986;106-116.
20. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. Biological Chemistry. 273:1998;24266-24271.
21. Laufs U., Kilter H., Konkol C., Wassmann S., Bohm M., Nickenig G. Impact of HMC CoA reductase inhibition on small GTPases in the heart. Cardiovascular Research. 53:2002;911-920.
22. Lee T.M., Chou T.F., Tsai C.H. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: Role of 8-iso-prostaglandin F-2 alpha formation. Journal of Cardiovascular Pharmacology. 40:2002;868-874.
23. Luo J.D., Zhang W.W., Zhang G.P., Guan J.X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology. 26:1999;903-908.
24. Luo J.D., Xie F., Zhang W.W., Ma X.D., Guan J.X., Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. British Journal of Pharmacology. 132:2001;159-164.
25. Luvara G., Pueyo M.E., Philippe M., Mandet C., Savoie F., Henrion D., Michel J.B. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall. Prevention by angiotensin II antagonism. Atherosclerosis and Thrombosis in Vascular Biology. 18:1998;1408-1416.
26. Matsuoka H., Nakata M., Keisuke K., Koga Y., Nomura G., Toshima M., Imaizumi T. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension. 27:1996;14-18.
27. Nahrendorf M., Hu K., Hiller K.H., Galuppo P., Fraccarollo D., Schweizer G., Haase A., Ertl G., Bauer W.R., Bauersachs J. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. Journal of the American College of Cardiology. 40:2002;1695-1700.
28. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., Quinones M.A., Zoghbi W.A., Entman M.L., Roberts R., Marian A.J. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 104:2001;317-324.
29. Pereira L.M., Mandarim-de-Lacerda C.A. Stereology of cardiac hypertrophy induced by NO blockade in rats treated with enalapril and verapamil. Analytical Quantitative Cytology and Histology. 23:2001;330-338.
30. Pereira L.M., Mandarim-de-Lacerda C.A. Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study. Journal of Cellular and Molecular Medicine. 6:2002;49-57.
31. Pechanova O., Bernatova I., Pelouch V., Simko F. Protein remodeling of the heart in NO-deficient hypertension: the effect of captopril. Journal of Molecular and Cellular Cardiology. 29:1997;3365-3374.
32. Pechanova O., Bernatova I., Pelouch V., Babal P. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiological Research. 48:1999;353-362.
33. Rossi M.A., Colombini-Netto M. Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta. Journal of Hypertension. 19:2001;1567-1579.
34. Sambrook J., Fritsch E.F., Maniatis T. Isolation of DNA from mammalian cells. Ford N. Molecular cloning. A laboratory manual. 1989;9.16-9.19 Cold Spring Harbor Laboratory Press, New York.
35. Sventek P., Li J.S., Grove K., Deschepper C.F., Schiffrin E.L. Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension. 7:1996;49-55.
36. Simko F. Pathophysiological principles of the relation between myocardial hypertrophy of the left ventricle and its regression. Physiological Research. 43:1994;259-266.
37. Simko F. Left ventricular hypertrophy regression as a process with variable biological implications. Canadian Journal of Cardiology. 12:1996;507-551.
38. Simko F., Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiological Reseach. 49:2000;37-46.
39. Simko F. Physiologic and pathologic myocardial hypertrophy: physiologic and pathologic regression of hypertrophy? Medical Hypotheses. 58:2002;11-14.
40. Simko F., Luptak I., Matuskova J., Babal P., Pechanova O., Bernatova I., Hulin I. Heart remodeling in the hereditary hypertriglyceridemic (hHTG) rat: effect of captopril and nitric oxide deficiency. Annals of the New York Academy of Sciences. 967:2002;454-462.
41. Takase H., Moreau P., Kung C.F., Nava E., Lüscher T.F. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension. 27:1996;25-31.
42. Takemoto M., Egashira K., Usui M., Numaguchi K., Tomita H., Tsutsui H., Shimokawa H., Sueishi K., Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. Journal of Clinical Investigation. 99:1997;278-287.
43. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation. 108:2001;1429-1437.
44. Usui M., Ichiki T., Katoh M., Egashira K., Takeshita A. Regulation of Ang II receptor expression by nitric oxide in rat adrenal gland. Hypertension. 32:1998;527-533.
45. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signalling networks. Genes and Development. 11:1997;2295-2322.
46. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., Itter G., Rosen R., Bohm M., Nickening G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 37:2001;1450-1457.